Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 106, Issue 9, Pages 1475-1480
Publisher
Springer Nature
Online
2012-03-23
DOI
10.1038/bjc.2012.89
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy
- (2011) Camillo Porta et al. BMC CANCER
- Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma
- (2011) Camillo Porta et al. EUROPEAN JOURNAL OF CANCER
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- Treatment-Associated Adverse Event Management in the Advanced Renal Cell Carcinoma Patient Treated with Targeted Therapies
- (2011) A. Ravaud ONCOLOGIST
- Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma
- (2010) Dorothy A. White et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2010) B. Escudier et al. ANNALS OF ONCOLOGY
- Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab
- (2010) Jorge A. Garcia et al. CANCER
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- (2010) Robert J. Motzer et al. CANCER
- Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR Inhibitors in Metastatic Renal Cell Carcinoma
- (2010) Giuseppe Di Lorenzo et al. EUROPEAN UROLOGY
- EAU Guidelines on Renal Cell Carcinoma: The 2010 Update
- (2010) Börje Ljungberg et al. EUROPEAN UROLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review
- (2009) Toni K. Choueiri et al. BJU INTERNATIONAL
- Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
- (2009) Brett E. Houk et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- EORTC-GU group expert opinion on metastatic renal cell cancer
- (2009) Theo M. de Reijke et al. EUROPEAN JOURNAL OF CANCER
- Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer
- (2009) Giuseppe Di Lorenzo et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now